Alcohol Withdrawal Clinical Trial
Official title:
Evaluation of Bilateral HF-rTMS Over DLPFC in add-on to Usual Treatment on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction After Withdrawal
High frequency repetitive transcranial magnetic stimulation (HF-rTMS) over dorsolateral prefrontal cortex (DLPFC) could correct defective executive functions over the hyperactive reward circuit through the meso-fronto-limbic connections. The restored cortical inhibitory control over compulsive alcohol use, could improve abstinence after withdrawal. The goal of this study is to evaluate the efficacy of HF-rTMS over DLPFC in AUD patients with executive dysfunction after withdrawal.
PARTICIPANTS: Participants with AUD (moderate to mild according to Alcohol Dependance Scale) with executive dysfunctions will be randomized. DESIGN: This study is a multicenter pilot double blind randomized controlled trial. After at least seven days of alcohol residential detoxification, executive dysfunctions's participants will be tested. 64 of them with executive dysfunctions will be randomized either in the active rTMS group or in the sham rTMS group. TMS will be performed during hospitalisation over 10 days. rTMS are proposed as an add on to the usual treatment. INTERVENTION: 20 rTMS (twice a day) will be performed 10 consecutive working days. The target of the rTMS will be the DLPFC (left side in the morning, right side in the afternoon). During each rTMS sessions (active and sham), alcohol related pictures from the Geneva Appetitive alcohol Pictures will be presented.In the active arm, rTMS will be performed with high frequency (20hz, 1500 pulses per session, 110% of motor threshold).In the control group, sham rTMS will be performed. Participants will be follow up to three months after the end of rTMS treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03916939 -
Osteopathic Treatment to Alcohol Withdrawal Syndrome
|
N/A | |
| Completed |
NCT04858490 -
Remote Treatment of Alcohol Withdrawal
|
N/A | |
| Recruiting |
NCT04876443 -
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
|
||
| Completed |
NCT05131334 -
Auricular Vagal Stimulation in Alcohol Craving
|
N/A | |
| Completed |
NCT02349477 -
Gabapentin for Alcohol Relapse Prevention
|
Phase 2 | |
| Terminated |
NCT01937364 -
Preventing Alcohol Withdrawal With Oral Baclofen
|
Phase 2 | |
| Completed |
NCT05393544 -
Digitally Assisted Recovery Coach
|
N/A | |
| Completed |
NCT00523185 -
A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
|
N/A | |
| Completed |
NCT01573052 -
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
|
Phase 4 | |
| Enrolling by invitation |
NCT06173973 -
Effects of Ketone Supplementation on Acute Alcohol Withdrawal
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03737864 -
NCARE, Transition to Recovery
|
N/A | |
| Recruiting |
NCT03878225 -
Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans?
|
N/A | |
| Terminated |
NCT03586089 -
Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
|
N/A | |
| Recruiting |
NCT04156464 -
Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
|
Phase 4 | |
| Completed |
NCT02202148 -
Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal
|
N/A | |
| Completed |
NCT02251912 -
Oxytocin Treatment of Alcohol Dependence
|
Phase 2 | |
| Completed |
NCT01212185 -
Oxytocin Treatment of Alcohol Withdrawal
|
Phase 1 | |
| Recruiting |
NCT04793685 -
Prazosin for Alcohol Use Disorder With Withdrawal Symptoms
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04159909 -
Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal
|
N/A | |
| Completed |
NCT05563350 -
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
|